Sinovac Bio · ISIN: AGP8696W1045

Newly Elected Directors of Sinovac Hold the First Board Meeting

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan an...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 10.07.2025 | 13:23
10 July 2025 01:23PM
Newly Elected Directors of Sinovac Hold the First Board Meeting
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan an...
Sinovac Bio
© BusinessWire
09 July 2025 07:17AM
Sinovac Shareholders Vote to Remove Current Directors and Elect SAIF Partners Nominees to Board at Special Meeting
SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), today announced that Sinovac Biotech Ltd. (“Sinovac” or the “Company”) shareholders voted to approve SAIF Partners’ proposals to remove the Company’s incumbent directors and to elect SAIF Partners’ slate of ten highly qualified director nominees to the Board of Directors (the “Board”) at Sino...
Sinovac Bio
© BusinessWire
09 July 2025 07:05AM
Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote
Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the Court of Appeals of the Eastern Caribbean Supreme Court granted a motion to stay the self-interested injunction s...
Sinovac Bio
© BusinessWire
02 July 2025 04:55PM
United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac
Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the United States District Court of Massachusetts (“the Court”) granted Vivo’s motion for a preliminary injunction ag...
Sinovac Bio
© BusinessWire
02 July 2025 03:20PM
SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”) which beneficially owns approximately 15% of the Company’s outstanding common shares, today urged shareholders to immediately vote “FOR” the election of SAIF Partners’ ten highly qualified director candidates to...
Sinovac Bio
© BusinessWire
02 July 2025 03:20PM
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
Third paragraph, second sentence of release should read: These include the current Board’s failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac’s prior public accounting firm to resign in April, and it...
Sinovac Bio
© BusinessWire
01 July 2025 09:02PM
SAIF Partners Sends Letter to Sinovac Shareholders
SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board’s empty promises to shareholders, numerous failures overseeing the Company, and c...
Sinovac Bio
© BusinessWire
24 June 2025 10:13PM
SAIF Partners Sends Open Letter to Sinovac Shareholders Outlining Current Board’s Failure to Act in the Interests of Shareholders
SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to its fellow Sinovac shareholders exposing the current Sinovac Board’s failure to act in the interest of all shareholders resulting...
Sinovac Bio
© BusinessWire
22 June 2025 03:20AM
Prime Success Issues Statement on New York State Court Decision Confirming Our Rights as Sinovac Shareholders – Including Right to Vote at Upcoming Special Meeting
Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the decision by the United States District Court for the Southern D...
Sinovac Bio
© BusinessWire
18 June 2025 10:38AM
SINOVAC Announces New Board Member
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nomin...
Sinovac Bio
© BusinessWire
17 June 2025 01:35AM
Prime Success Sets the Record Straight Regarding Continued False and Misleading Statements from Sinovac Biotech’s Current Board
Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the Company’s continued false, misleading and outright fabricated c...
Sinovac Bio
© BusinessWire
16 June 2025 05:52PM
SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board
SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today announced that it has filed a definitive proxy statement for the election of ten director nominees to Sinovac’s Board of Directors (the “Board”) in...
Sinovac Bio
© BusinessWire
16 June 2025 06:50AM
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust...
Sinovac Bio
© BusinessWire
14 June 2025 06:00AM
Prime Success Responds to Sinovac Biotech’s False and Misleading Claims
Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued the following letter in response to the Company’s recent false and misleading claims relating...
Sinovac Bio
© BusinessWire
13 June 2025 01:04AM
SINOVAC’s Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00...
Sinovac Bio
© BusinessWire
11 June 2025 02:30PM
Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company’s False and Misleading Claims
Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today sent a letter to shareholders. *** Dear Fellow Sinovac Shareholders, We, Vivo Capital (“Vivo”), write to you as fellow...
Sinovac Bio
© BusinessWire
11 June 2025 01:00AM
Prime Success Sends Letter to Sinovac Biotech Shareholders
Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a letter to shareholders in connection with the upcoming Special Meeting of Shareholders (the...
Sinovac Bio
© BusinessWire
23 May 2025 04:00AM
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 16, 2025 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq Listing Rule 5250...
Sinovac Bio
© BusinessWire
30 April 2025 08:00AM
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET....
Sinovac Bio
© BusinessWire
29 April 2025 09:29AM
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitim...
Sinovac Bio
© BusinessWire
24 April 2025 03:00AM
Vivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board’s Value Destructive Actions
Vivo Capital (“Vivo” or the “Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, today announced multiple legal proceedings to challenge the irresponsible actions taken by the current Board of Directors of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”) under the control of the activist inve...
Sinovac Bio
© BusinessWire
10 April 2025 10:01PM
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
BOSTON, April 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025.  More than a week after the dividend announcement, these simple and e...
Sinovac Bio
© PR Newswire
10 April 2025 09:58PM
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025.  More than a week after the dividend announcement, these simple and e...
Sinovac Bio
© PR Newswire
10 April 2025 09:54PM
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025.  More than a week after the dividend announcement, these simple and e...
Sinovac Bio
© PR Newswire
10 April 2025 09:44PM
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025.  More than a week after the dividend announcement, these simple and e...
Sinovac Bio
© PR Newswire
10 April 2025 09:44PM
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
BOSTON, April 10, 2025 /CNW/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025.  More than a week after the dividend announcement, these simple and essentia...
Sinovac Bio
© PR Newswire
01 April 2025 06:48AM
SINOVAC Announces Decision to Declare Cash Dividend
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company’s board of directors (the “Board”) has decided to declare a special cash dividend of US$55.00 per common share (the “Dividend”). The Board expects to fund the Dividend from available cash reso...
Sinovac Bio
© BusinessWire
28 March 2025 12:00PM
SINOVAC Announces New Board Member and Chairman of the Audit Committee
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under N...
Sinovac Bio
© BusinessWire
20 March 2025 04:24PM
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically...
Sinovac Bio
© PR Newswire
20 March 2025 04:20PM
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically...
Sinovac Bio
© PR Newswire
20 March 2025 04:15PM
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically...
Sinovac Bio
© PR Newswire
20 March 2025 04:05PM
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically...
Sinovac Bio
© PR Newswire
20 March 2025 04:05PM
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
BOSTON, March 20, 2025 /CNW/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng...
Sinovac Bio
© PR Newswire
28 February 2025 01:00PM
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, that...
Sinovac Bio
© BusinessWire
16 January 2025 02:01PM
SINOVAC Issues Statement Regarding Privy Council Judgment
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board...
Sinovac Bio
© BusinessWire
16 December 2024 11:04AM
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet b...
Sinovac Bio
© BusinessWire
16 August 2024 02:54PM
SINOVAC Reports Unaudited First Half of 2024 Financial Results
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2024. First Half of 2024 Financial Summary Sales for the six months ended June 30, 2024 were $121.3 million, compared to $140.4 million in...
Sinovac Bio
© BusinessWire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.